Find below a list of all Satellite Symposia of EANM’26.
The content presented on this page is constantly updated.
Symposium1
Medscape Education Global Sunday, October 18, 2026 (13:15 – 14:45)
Hall F1
Content/Abstracts/Speakers will be mentioned here as soon as confirmed.
Symposium2
Telix Pharmaceuticals Sunday, October 18, 2026 (13:15 – 14:45)
Hall F2 (livestream available)
« The Future Doesn’t Wait: The Next Era of Theranostics in Urologic Oncology » chaired by Jeremie Calais.
Symposium3
ABX advanced biochemical compounds Sunday, October 18, 2026 (13:15 – 14:45)
Hall G2
Content/Abstracts/Speakers will be mentioned here as soon as confirmed.
Symposium4
Siemens Healthineers Sunday, October 18, 2026 (13:15 – 14:45)
Hall K (livestream available)
Symposium title:
Evolution in action: Advancing our molecular imaging portfolio
Program text:
Discover how continuous innovation is shaping the future of molecular imaging at this lunch symposium, which highlights evolving developments across PET/CT, PET/MR and AI tools. Learn about improved time-of-flight performance on the Biograph Quadra PET/CT, AI-assisted reading and reporting with syngo.via, and more.
Symposium5
GE Healthcare (PDx) Sunday, October 18, 2026 (13:15 – 14:45)
Hall G1
TITLE
Molecular Imaging in Dementia and Co-Pathologies with Alzheimer Disease
Molecular Imaging in Dementia and Co-Pathologies with Alzheimer Disease
Moderator:
Pr Antoine Verger, Nuclear Physician (CHRU Nancy, France)
Pr Antoine Verger, Nuclear Physician (CHRU Nancy, France)
AGENDA:
- Pr Federica Agosta, Neurologist (UniSR, Milan, Italy)
When Dementia Overlaps: The Clinical Impact of Co-Pathologies with Alzheimer’s Disease - Pr Matthias Brendel, Nuclear Physician (University of Munich, Germany)
Molecular Imaging at the DLB–AD Intersection: Differential Diagnosis and Co-Pathology in Practice - Pr Dr Javier Arbizu, Nuclear Physician (University of Navarra, Spain)
Relevance of amyloid PET Imaging in AD diagnosis
SUMMARY
This symposium explores the growing role of molecular imaging in improving the diagnosis and management of dementia, starting from the complex overlap between Alzheimer’s disease (AD) and other neurodegenerative disorders. Through a multidisciplinary perspective combining neurology and nuclear medicine, the faculty will discuss how co-pathologies can influence clinical presentation, diagnostic pathways, and patient management.
Topics include the clinical impact of overlapping dementia pathologies, the value of molecular imaging in differentiating Dementia with Lewy Bodies (DLB) from Alzheimer’s disease, and the role of amyloid PET imaging in supporting accurate and timely AD diagnosis. Together, these sessions highlight how advanced imaging techniques can help clinicians navigate diagnostic complexity and enable more personalized patient care.
Symposium6
GE Healthcare Monday, October 19, 2026 (13:15 – 14:45)
Hall B
Content/Abstracts/Speakers will be mentioned here as soon as confirmed.
Symposium7
Curium Monday, October 19, 2026 (13:15 – 14:45)
Hall F1
Content/Abstracts/Speakers will be mentioned here as soon as confirmed.
Symposium8
Novartis Pharma Monday, October 19, 2026 (13:15 – 14:45)
Hall F2 (livestream available)
Shaping the Future of Radioligand Therapy: From Drug Development to Clinical Application
Summary:
This expert-led symposium brings together a multidisciplinary faculty to explore the evolving landscape of radioligand therapy (RLT) development—from foundational principles and approved therapies to novel targets, radionuclides, and indications. The panel will discuss key challenges and opportunities in early clinical development, including the role of dosimetry, safety reference thresholds, and other available evidence to inform development decisions. The symposium will conclude by looking ahead to what is needed to successfully integrate novel RLTs into routine clinical practice.
Faculty:
• Chair: Ken Herrmann, University Hospital Essen, Essen, Germany
• Christophe Deroose, University Hospitals Leuven, Leuven, Belgium
• Oliver Sartor, East Jefferson General Hospital Cancer Center, New Orleans, LA, USA
• Caroline Stokke, Oslo University Hospital Oslo, Norway
Agenda:
13:15–13:20
Welcome, introduction, and educational objectives
Ken Herrmann (Chair & Moderator)
13:20–13:25
History and evolution of radioligand therapies
Ken Herrmann
13:25–13:45
The evolving radioligand therapy landscape: Building on an established platform to unlock novel opportunities
All faculty
13:45–14:30
Navigating early clinical development of radioligand therapies: Challenges and opportunities
All faculty
14:30–14:40
Novel radioligand therapies in clinical practice: Meeting today’s needs, shaping tomorrow’s standards
All faculty
14:40–14:45
Conclusion and key takeaways
Ken Herrmann
Symposium9
United Imaging Healthcare Monday, October 19, 2026 (13:15 – 14:45)
Hall K (livestream available)
Content/Abstracts/Speakers will be mentioned here as soon as confirmed.
Symposium10
BlueEarth Diagnostics Monday, October 19, 2026 (13:15 – 14:45)
Hall G1 (livestream available)
Content/Abstracts/Speakers will be mentioned here as soon as confirmed.
Symposium11
Spectrum Dynamics Medical Monday, October 19, 2026 (13:15 – 14:45)
Hall E2
EANM Spectrum Dynamics Symposium – “Driving Precision Nuclear Medicine with 360° CZT SPECT/CT: Quantitation, AI, and Clinical Impact”
Pr. Denis Agostini MD PhD
Host, Moderator, Introductions
Laetitia Imbert, PhD
360 CZT SPECT/CT Quantitation and validation of high energy and AI applications
Désirée DEANDREIS, MD PhD
From Discovery to Daily Practice: Clinical and Research Applications of VERITON-CT CZT SPECT/CT in Oncology and Theranostics
Daniel Juneau, MD
Optimizing clinical and research workflows in a large tertiary center using a 360 CZT SPECT/CT
Symposium12
OmniAb Tuesday, October 20, 2026 (13:15 – 14:45)
Hall G1
Title: OmniUltra™: An In Vivo Discovery Platform for Structured Peptides to Enable Radioligand Therapy
Speaker: Christel Iffland, PhD, Sr. Vice President, R&D Portfolio Management and Technology Operations, OmniAb
Summary: OmniUltra is an in vivo discovery platform designed to identify compact, target-selective peptide ligands with potential advantages for radioligand therapy and other applications. Peptides are generated and optimized in vivo, using natural selection mechanisms to enrich for high-affinity target engagement, specificity, favorable size, and tunable pharmacokinetic clearance. OmniUltra harnesses immune-system biology which may enable identification of drug-like binders earlier in discovery compared to traditional approaches.